MetrioPharm AG Expands Patent Protection for its Lead Compound MP1032 to Canada
Zurich, November 15, 2018. MetrioPharm AG announces that a substance patent for its lead compound MP1032 has been obtained in Canada. The Canadian patent CA 2791327 was granted on October 30, 2018.
MetrioPharm AG now has broad protection for MP1032 in all major markets: In Europe, the United States, Australia, New Zealand, Israel, China, Japan, Russia, South Africa, the Republic of Korea and now also in Canada (see map). In other countries, the application or partial applications are still being examined.
"The grant of the Canadian patent is another important success of our ongoing patent work and an important building block for our global strategy. Canada already has a pharmaceutical market volume of CAD 25 billion and a sustained annual growth rate. Together with the USA, we have now covered the entire North American continent," comments Dr. Wolfgang Brysch, CEO of MetrioPharm AG.
About MP1032
MP1032 is the lead compound of a class of proprietary immune modulators developed by MetrioPharm. MP1032 is believed to modulate the oxidative stress-mediated activation state of macrophages and downregulate the M1 state. In contrast to other immune-modulating and disease-modifying drugs, MP1032 does not impact T-cells and preferentially affects macrophages at the sites of inflammation. MP1032 has shown anti-inflammatory activity in animal models of disease and a favorable toxicology profile in pre-clinical studies.
For the first Phase II study with MP1032, the indication psoriasis was selected because this immune-induced inflammatory disease is regarded as a so-called »door-opener indication«. Successes in the treatment of psoriasis have already led to first indications of promise for use in other chronic inflammatory diseases, such as arthritis and multiple sclerosis.
About MetrioPharm
MetrioPharm AG is a pharmaceutical biotech company developing drugs for chronic inflammatory diseases such as psoriasis, arthritis, and multiple sclerosis. Such chronic diseases pose the greatest individual health risk. The goal of MetrioPharm AG is to make the therapy of chronic inflammatory diseases more effective and more tolerable. We hope to achieve a healthspan expansion for patients: We want to stop the progression of chronic inflammatory diseases as early as possible and significantly prolong the healthy lifespan of millions of people.
MetrioPharm AG was founded in 2007 and is headquartered in Zurich with research facilities in Berlin.
Forward-looking statements
This press release contains forward-looking statements that involve risks and uncertainties and are consistent with MetrioPharm's assessment as of the date of this release. Such forward-looking statements are neither promises nor guarantees, but are subject to numerous risks and uncertainties, many of which are beyond MetrioPharm's control, that could cause actual results to differ materially from those contemplated in these forward-looking statements. MetrioPharm does not assume any obligation to update forward-looking statements with respect to changed expectations or new events, conditions or circumstances on which these statements are based. A liability or guarantee and, if applicable, claims for topicality, correctness and completeness of these data and information are excluded and cannot be derived either explicitly or impliedly.
Your Contact
Eva Brysch
Head of Investor Relations & Corporate Communications
MetrioPharm AG
Bleicherweg 45
CH-8002 Zurich
MetrioPharm Deutschland GmbH
Am Borsigturm 100
D-13507 Berlin
T +49 (0) 30 33 84 395 40
F +49 (0) 30 33 84 395 99
E invest@metriopharm.com
W www.metriopharm.com